COSCIENS Biopharma Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Peter Harry Puccetti
- Full Time Employees
- 28
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 22 Adelaide Street West Toronto ON Canada M5H 4E3
- IPO Date
- Sep 18, 1996
- Website
- cosciensbio.com
- Similar Companies
- Business
- COSCIENS Biopharma Inc. is a life sciences company focused on the development, manufacture, and commercialization of natural active ingredients and pharmaceutical products for cosmeceutical, nutraceutical, and diagnostic markets. The company operates through two core segments: natural active ingredients and pharmaceutical products. Its natural ingredient portfolio includes Avenanthramides and Beta Glucan derived from plant and microbial sources, used in skincare, nutraceutical, and health-related applications, supported by proprietary extraction and manufacturing technologies. Its pharmaceutical product line centers on Macimorelin acetate (Macrilen/Ghryvelin), an oral peptidomimetic ghrelin receptor agonist that stimulates growth hormone secretion and supports diagnostic testing for growth hormone deficiency, with broader potential exploration in endocrinology and oncology indications. COSCIENS provides formulation development, regulatory support, and contract manufacturing services to customers across global markets, including the United States, Europe, and other international regions, and maintains ongoing clinical development programs targeted at expanding its therapeutic and diagnostic offerings. The company emphasizes strategic partnerships, pipeline prioritization, and operational integration with its merger-related initiatives to accelerate product development and commercialization, while maintaining a focus on natural-based products and therapeutic diagnostics. COSCIENS is headquartered in Frankfurt am Main, Germany, and maintains a broader international footprint through collaborations, product licenses, and distribution arrangements to serve dermatology, nutraceuticals, and clinical diagnostics markets. Since its inception, the company has pursued growth through research and development investments, strategic alliances, and product portfolio enhancements to broaden its exposure to high-value natural ingredient markets and specialized pharmaceutical diagnostics. Founding year and specific corporate history are aligned with ongoing corporate restructuring and strategic realignments designed to sharpen its pure-play natural products focus while sustaining pharmaceutical and diagnostic capabilities. Subsidiaries and related entities participate in technology transfer, contract manufacturing, and regulatory compliance activities to support global commercialization efforts. The company’s latest changes include ongoing merger integration with Ceapro Inc., advancement of Phase 1/2a clinical programs for avenanthramide-based products, leadership appointments to steer strategic direction, and continued expansion into nutraceutical and cosmeceutical markets through partnerships, licensing, and additional capital deployment. These developments position COSCIENS as a diversified provider of natural actives and diagnostic-pharma products with a global reach across key markets and customer types in cosmetics, healthcare, and clinical research sectors.
Company News
COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
COSCIENS COMPLETES SECOND TRANCHE OF CONVERTIBLE DEBENTURE OFFERING
COSCIENS ACQUIRES NUALTIS CORP.
COSCIENS Biopharma Inc. Reports Q2 2026 Results
COSCIENS Biopharma Inc. Completes Share Capital Amendment
COSCIENS Biopharma Inc. Completes Share Capital Amendment
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
COSCIENS Biopharma Inc. Reports Q1 2026 Results
COSCIENS Biopharma Inc. Reports Q1 2026 Results
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
COSCIENS Comments on Unusual Market Activity
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
COSCIENS Provides Strategic Update
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
Fueled by Precision and Performance, President Daniel Goldburg Leads CSCI Into Its Next Chapter as Florida's Premier Structural Shell Contractor
COSCIENS Biopharma Inc. Announces Leadership Change
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders